Arcturus Therapeutics Holdings (ARCT) Change in Accured Expenses (2018 - 2026)

Arcturus Therapeutics Holdings has reported Change in Accured Expenses for 9 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 85.04% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$8.3 million (down 77.53% YoY), and the FY2025 full-year result was -$15.3 million, down 357.33% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.2 million, down from $4.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $9.4 million in Q2 2022, with the low at -$8.2 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged -$100647.1 across 5 years, with a median of -$454000.0 in 2023.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 178.73% — and 2025, when it tumbled 2174.66%.
• Arcturus Therapeutics Holdings' Change in Accured Expenses stood at $7.4 million in 2022, then plunged by 61.65% to $2.8 million in 2023, then soared by 130.15% to $6.6 million in 2024, then plunged by 32.09% to $4.5 million in 2025, then sank by 127.69% to -$1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.2 million (Q1 2026), $4.5 million (Q4 2025), and -$5.4 million (Q3 2025), per Business Quant data.